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In the last decade, metabolomics has experienced significant advances in the throughput and robustness
of analytical methodologies. Yet the preparation of biofluids and low-mass tissue samples remains a
laborious and potentially inconsistent manual process, and a significant bottleneck for high-throughput
metabolomics. To address this, we have compared three different sample extraction solvent systems in
three diverse sample types with the purpose of selecting an optimum protocol for subsequent auto-
mation of sample preparation. We have investigated and re-optimised the solvent ratios in the recently
introduced methyl tert-butyl ether (MTBE)/methanol/water solvent system (here termed modified
Matyash; 2.6/2.0/2.4, v/v/v) and compared it to the original Matyash method (10/3/2.5, v/v/v) and the
conventional chloroform/methanol/water (stepwise Bligh and Dyer, 2.0/2.0/1.8, v/v/v) using two bio-
fluids (human serum and urine) and one tissue (whole Daphnia magna). This is the first report of the use
of the Matyash method for extracting metabolites from the US National Institutes of Health (NIH) model
organism D. magna. Extracted samples were analysed by non-targeted direct infusion mass spectrometry
metabolomics or LC-MS metabolomics. Overall, the modified Matyash method yielded a higher number
of peaks and putatively annotated metabolites compared to the original Matyash method (1e29% more
peaks and 1e30% more metabolites) and the Bligh and Dyer method (4e20% more peaks and 1e41%
more metabolites). Additionally the modified Matyash method was superior when considering metab-
olite intensities. The reproducibility of the modified Matyash method was higher than other methods (in
10 out of 12 datasets, compared to the original Matyash method; and in 8 out of 12 datasets, compared to
the Bligh and Dyer method), based upon the observation of a lower mRSD of peak intensities. In
conclusion, the modified Matyash method tended to provide a higher yield and reproducibility for most
sample types in this study compared to two widely used methods.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Metabolomics has now matured into a routinely usedB.V. This is an open access article utechnology for measuring themetabolic phenotypes of awide array
of sample types e including biofluids, cells and tissues e derived
from plants, animals andmicrobes. One recent and important trend
has been towards large-scale studies, in particular within
biomedical and toxicological metabolic profiling [1-3]. While the
necessary automation of data generation to support such large-
scale studies is occurring [4, 5], and the automation of datander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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extraction of metabolites from biological samples remains a largely
manual bottleneck in the metabolomics pipeline [8]; it is both a
challenge for large-scale biofluid studies and an unsolved problem
for studies of tissues, particularly the low-mass. High analytical
reproducibility and throughput of the sample preparation step are
crucial factors when measuring the metabolite compositions of
hundreds to thousands of samples; however this is difficult to
achieve using laborious manual extraction protocols. With ad-
vances in robotic technologies, automated sample handlers have
the potential to replace manual sample processing inmetabolomics
[9], promising to open new horizons for large-scale studies.
The appropriate selection of extraction solvents has been a focus
of the metabolomics community for several years [10-14]. Multiple
factors should be considered: from maximising the chemical space
of metabolites that are extracted through to maximising its oper-
ational simplicity, efficiency, reproducibility, speed and safety. The
method first proposed by [15], which was originally intended to
extract lipids, has proven so successful that it has been adopted by
multiple laboratories worldwide [8, 16, 17]. This method utilises a
chloroform/methanol/water (2/2/1.8, v/v/v) biphasic solvent sys-
tem to extract both polar (methanol/water phase) and non-polar
(chloroform phase) compounds separately. The extraction effi-
ciency of chloroform stems from its ability to associate with water
molecules through weak hydrogen bonds [18]. However, this sol-
vent system has drawbacks, not least that chloroform is a carcin-
ogen. Furthermore, the biphasic extraction results in a layer of
protein and cellular debris between the upper polar and lower non-
polar phases (called the interphase), which hinders the clean
aspiration of the lower phase. While this is a known difficulty for
manual liquid:liquid extractions, it represents a particular chal-
lenge for automated extractions using a liquid handling robot.
Significant efforts have been devoted to find an alternative to
the Bligh and Dyer method such as hexane/isopropanol e 3/2, v/v
[19], dichloromethane/methanol e 2/1, v/v [20], and hexane/
ethanol e 5/2, v/v [21]. None of them, however, were reported to
surpass the Bligh and Dyermethod in terms of extraction efficiency.
More recently, the Matyash method [22] was reported, which
claimed to be at least as efficient as the chloroform/methanol/water
method, and benefited from replacing chloroform by methyl-tert-
butyl ether (MTBE), which is non-carcinogenic. The Matyash
method (MTBE/methanol/water) utilises a non-polar phase (largely
MTBE) that has a lower density than themethanol/water phase and
hence it partitions on the top of the biphasic solvent system; this
allows easier recovery of the lipid layer but correspondingly more
difficult removal of the polar layer. More importantly e in terms of
automation compatibility e the protein and cell debris layer is
forced to the bottom of the sample tube following centrifugation,
simplifying the removal of both solvent phases during the extrac-
tion. The Matyash method has been evaluated in animal [23-25]
and plant samples [26, 27], proving its efficiency. The original
method, however, is primarily focused on lipid extraction and un-
like the Bligh and Dyer method has not been optimised for the
recovery of both polar and non-polar metabolites from low-mass
samples [8].
Here we have studied the extraction of two biofluids (human
plasma and urine) and one tissue type (whole water flea Daphnia
magna) in order to select a metabolite extraction protocol that of-
fers superior metabolite yield and reproducibility and provides the
highest benefit for automation (in terms of method duration, use of
resources, simplicity to automate). We compare the gold-standard
Bligh and Dyer extraction method (chloroform/methanol/water,
stepwise) to two variations of the Matyash method (MTBE/meth-
anol/water) e the original published protocol (MTBE/methanol/
water, 10/3/2.5, v/v/v) and a modified method (MTBE/methanol/water, 2.6/2.0/2.4, v/v/v) e the latter employs solvent ratios that
match those used by the Bligh and Dyer method and thereby in-
crease the volume of the polar phase for easier handling. Specif-
ically, we compare the extraction yields, derived from
measurements of the number of peaks and putatively annotated
metabolites detected in ultra performance liquid chromatography-
mass spectrometry (UHPLC-MS) and direct infusion mass spec-
trometry (DIMS), and extraction reproducibilities, calculated as the
median relative standard deviation e mRSD [28] of all detectable
metabolites.
2. Materials and methods
2.1. Biological samples
Three well studied yet diverse sample types were selected to
ensure our results are widely applicable: two human biofluids,
plasma and urine, and a toxicological and US National Institutes of
Health model organism (D. magna). Biofluids (100 ml aliquots from
pooled frozen samples) were acquired from Sera Laboratories In-
ternational Ltd (West Sussex, UK). D. magna was cultured in OECD
media, fed on Chlorella sp., and <24 h neonates (30 animals per
sample, flash frozen in liquid nitrogen and stored at 80 C) were
used for experiments [29].
2.2. Metabolite extraction methods
Three extraction protocols were compared e Bligh and Dyer
method (chloroform/methanol/water, 2/2/1.8, v/v/v) as optimised
for metabolomics studies of tissues [8], the original Matyash
method (MTBE/methanol/water, 10/3/2.5, v/v/v; [22]) and our
modification of the Matyash method (MTBE/methanol/water, 2.6/
2.0/2.4, v/v/v) to use solvent ratios and volumes that were equiv-
alent to the successful Bligh and Dyer method and that were
compatible with the automated extraction of both the polar and
non-polar phases. Biofluids were extracted using the same pro-
tocols, however, without homogenization. Each method is
described in more detail in the following sections. For each sample
type-extraction method combination, 10 replicates were used.
2.3. Bligh and Dyer (stepwise) method
As described byWu et al. [8], with someminor changes, first 75%
ice cold methanol (32 ml mg1 methanol and 10.6 ml mg1 or
0.9 ml mg1 HPLC water for tissues and biofluids, respectively) was
added to samples and they were homogenised (tissue only) in a
Precellys-24 bead-based homogeniser (Bertin technologies) for
2 10s bursts at 6400 rpm. Homogenates were each transferred
into 1.8ml glass vials and 16 ml mg1 (or 2 ml mg1 for biofluids) of
chloroform was added. Samples were mixed using a Bioshake
platform (2000 rpm, 3min; Bioshake 3000 elm (Edge Locking
Mechanism), Quantifoil Instruments GmbH) and then centrifuged
(2415 g, 10min, 18 C; refrigerated centrifuge 6-16KR, Sigma) to
pellet the protein and tissue debris. Each monophasic supernatant
(~500 ml) was transferred to a clean 1.8ml glass vial and phase
separation was induced by adding 16 ml mg1 (or 2 ml mg1 for
biofluids) of chloroform and 18.2 ml mg1 (or 2.27 ml mg1 for bio-
fluids) of HPLC water. Samples were then mixed again on the Bio-
shake (2000 rpm, 1min), incubated at 18 C for 10min to allow the
partitioning of the solvent system and then centrifuged (2415 g,
10min, 18 C). Polar and non-polar fractions were aliquoted into
clean Eppendorf tubes or glass vials, respectively, and then dried
down using a SpeedVac concentrator (SPD111V, Thermo Savant; for
polar samples only) or nitrogen blow-down evaporator (TECHNE
sample concentrator with Peak Scientific Genius nitrogen
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2.4. Matyash method
This method followed the original Matyash extraction [22] with
some minor modifications in order to make all methods compa-
rable. Samples were homogenised (tissue only) in 75% cold meth-
anol as in section 2.3 and homogenates were transferred into 1.8ml
glass vials. Then 107 ml mg1 (or 13.3 ml mg1 for biofluids) of MTBE
was added to each vial and the samples were mixed on the Bio-
shake (2000 rpm, 3min). Phase separation was then induced by
adding 16.1 ml mg1 (or 2 ml mg1 for biofluids) of HPLC water.
Samples were thenmixed again on the Bioshake (2000 rpm,1min),
incubated at 18 C for 10min to allow phase separation to begin,
and centrifuged (2415 g, 10min, 18 C). Polar and non-polar
fractions were aliquoted into clean Eppendorf tubes or glass vials,
respectively, and dried as in 2.3.
2.5. Modified Matyash method
The solvent ratios used in this method were customised to
match those for the Bligh and Dyer protocol. This method was
identical to the Bligh and Dyer (stepwise), until the tissue ho-
mogenates were transferred into 1.8ml glass vials. MTBE
(16 ml mg1 or 2 ml mg1 for tissues and biofluids, respectively) was
then added and samples were mixed on a Bioshake (2000 rpm,
3min). Phase separation was induced by adding 25.6 ml mg1 (or
3.2 ml mg1 for biofluids) of MTBE and 27.8 ml mg1 (or 3.47 ml mg1
for biofluids) of HPLC water. Samples then were mixed on the
Bioshake (2000 rpm, 1min), incubated at 18 C for 10min, and
centrifuged (2415 g, 10min, 18 C). Polar and non-polar fractions
were aliquoted and then dried down as described in section 2.3.
2.6. Direct infusion mass spectrometry
Due to a low sample biomass and the superior sensitivity of the
method [29], D. magna samples (only) were analysed using SIM-
stitch direct infusion mass spectrometry (DIMS), as reported pre-
viously [30]. The rest of the sample types were analysed using
(UHPLC-MS). Dried polar extracts were resuspended in 80/20
methanol/water (HPLC grade) containing 0.25% formic acid for
positive ion mass spectrometry, or 80/20 methanol/water con-
taining 20mM ammonium acetate for negative ion analysis. Non-
polar extracts were resuspended in 2/1 methanol/chloroform
with 5mM ammonium acetate. Samples were analysed using a
Quadrupole-Orbitrap mass spectrometer (Q-Exactive, Thermo
Fisher Scientific, Hemel Hempstead, UK) equipped with a chip-
based direct infusion nano-ESI (electrospray ionisation) assembly
(Triversa, Advion Biosciences, Ithaca, NY, USA). Nano-ESI conditions
consisted of 0.3 psi backing pressure and 1.4 kV or 1.4 kV elec-
trospray voltage (for positive and negative ion analysis, respec-
tively), all controlled by ChipSoft software (version 8.3.3, Advion
Biosciences). The mass range was from 100 to 1000 Daltons (Da).
2.7. Ultra performance liquid chromatography e mass
spectrometry
Dried polar and non-polar extracts were resuspended as above.
Samples were analysed using a Quadrupole-Orbitrap mass spec-
trometer (Q-Exactive) equipped with a Dionex UltiMate 3000
UHPLC (ultra high performance liquid chromatography; Thermo
Fisher Scientific) employing reverse phase and HILIC (hydrophilic
interaction liquid chromatography) methods. For the reverse phase
analyses, solvents were composed of 0.1% formic acid in HPLCwater
(A) and 0.1% formic acid in methanol (B). For HILIC, the solventscontained 95% acetonitrile with the addition of 5 mM ammonium
formate (pH ¼ 3; A) and HPLC water with 5mM ammonium
formate (pH ¼ 3; B). Ion source conditions comprised: spray
voltage 3.5kV (for negative mode) and þ4.5kV (for positive
mode); resolution of 70,000 (for single polarity mode) and 35,000
(for polarity switching mode). The mass spectral range was from
100 to 1000 Da.
2.8. Data processing and analysis
SIM-stitch DIMS data comprised of a series of narrow over-
lappingmass windows that were processed as described previously
using custom-written Matlab software [30, 31]. In brief, only peaks
with a signal to noise ratio greater than 10, that passed the ‘repli-
cate filter’ (i.e. present in at least 2 of the 3 technical replicates per
sample), passed the blank filter (i.e. present in the biological sam-
ples with at least ten times the intensity of a potential occurrence in
the blank samples, designed to remove solvent and contaminant
peaks from the dataset), and that passed the ‘80% sample filter’ by
class (i.e. present in at least 80% of the biological replicates of any
one extraction method) were retained in the datasets. UHPLC-MS
data were processed applying the freely available software XCMS,
operated in R applying previously defined parameters [32]. Data
acquired applying DIMS and UHPLC-MS were normalized applying
probabilistic quotient normalisation (PQN) and SUM normalisation,
respectively. Relative standard deviation (RSD) of the peak in-
tensities was calculated across all the detected peaks and a single
median RSD was determined for each extraction method and ion
mode combination, where the median RSD value provides a mea-
sure of the reproducibility of that dataset [28]. It is important to
note that for each biofluid a pooled sample was investigated such
that any variability in the mass spectra would be known to arise
from the sample preparation and LC-MS measurements. For
Daphnia, each sample investigated was a different pool of 30 ani-
mals; hence while that biological pooling of animals (per sample)
greatly reduced the biological variability between the samples, the
variability in the mass spectra could arise from slight biological
differences between samples or from the metabolite extraction and
DIMS measurements. Peak counts (total number of peaks for each
of the three extraction methods), the corresponding m/z values
(DIMS) and m/z-retention time (rt) pairs (UHPLC-MS), and peak
intensities were extracted from the Matlab software. DIMS data
were then putatively annotated using MI-Pack v2_01 software
(based on Python 27) employing KEGG database and LIPIDMAPS for
polar and non-polar compounds, respectively (with the maximum
mass error of 3 ppm). LC-MS data were putatively annotated
employing PUTMEDID operated in the Taverna workflow environ-
ment applying standard parameters [33]. Venn diagrams were
created using Bioinformatics and Evolutionary Genomics website
tool at http://bioinformatics.psb.ugent.be/webtools/Venn/.
3. Results and discussion
3.1. Extraction yield
First, all extraction strategies were compared based upon the
number of peaks detected, for each sample type and for each mass
spectrometry ion mode (Fig. 1). In addition, Fig. 1 shows which
peaks are common across two or three of the extraction strategies.
Overall, the modified Matyash method yielded more peaks in bio-
fluids than both the original Matyash method (1e29% more; except
urine non-polar samples, where original Matyash yielded 4e7%
more peaks) and the Bligh and Dyer method (4e20% more; only in
non-polar negative plasma samples equal number of peaks was
generated) when combining results for the upper and lower phases
Fig. 1. Extraction method comparison based on peak counts as a surrogate measure of metabolite yield. Venn diagrams represent the numbers of unique and common peaks (and
relative percentages) between the three extraction methods: stepwise Bligh and Dyer e blue circle, Matyash modified e red circle, and original Matyash e green circle) in a-d)
D. magna, e-h) human plasma, and i-l) human urine (n¼ 10), for positive (a, e, i) and negative (b, f, j) ion analysis of polar metabolites, and positive (c, g, k) and negative (d, h, l) ion
analysis of non-polar metabolites.
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detected in only one out of three methods) than these two other
extraction methods. In D. magna samples on the other hand the
original Matyash method performed better than the other two
(yielding 1e5% more peaks than modified Matyash and 7e15%
more than the Bligh and Dyer method).
Specifically, in D. magna samples (Fig. 1 (aed)), the original and
modified Matyash methods showed very similar peak counts both
in the polar and non-polar phases with minimal unique peaks. The
Bligh and Dyer protocol performed slightly poorer (yielding 6e16%
fewer peaks), however generated the majority of unique peaks.
While some clear differences exist between the methods, between
73 and 76% of the peaks detected were extracted by all three pro-
tocols, highlighting the relative consistency of biphasic extractions
and DIMS analyses of this tissue type. In plasma samples (Fig. 1
(eeh)) the modified Matyash method showed superior results
yielding 27e29% and 16e20% more polar peaks than the original
Matyash and Bligh and Dyer methods, respectively (except for theanalyses of the non-polar fractions (Fig. 1 (g, h)) for which the Bligh
and Dyer method detected a comparable number of peaks to the
modified Matyash protocol). In urine samples (Fig. 1 (iel)) the
original Matyash method yielded the highest number of peaks
(4e7% and 14e18% more non-polar peaks than the modified
Matyash and Bligh and Dyer methods, respectively). In summary,
the original Matyash method showed superior extraction yield in
D. magna and urine samples (except for polar negative); the
modified Matyash method yielded a comparable (to the original
Matyash) number of peaks in D. magna and polar urine samples,
and was superior to the other two methods for non-polar plasma
samples; and the Bligh and Dyer method was comparable to the
modified Matyash method for non-polar plasma samples.
Furthermore, extraction methods were also compared based on
putatively annotated metabolites, for each sample type and ion
mode (Fig. 2). In general, and as anticipated, trends for metabolites
were consistent with trends for the number of peaks detected; the
modified Matyash method again performed better in biofluids than
Fig. 2. Extraction method comparison based on number of putatively annotated metabolites. Venn diagrams represent the numbers of unique and common metabolites (and
relative percentages) between the three extraction methods: stepwise Bligh and Dyer e blue circle, Matyash modified e red circle, and original Matyash e green circle) in a-d)
D. magna, e-h) human plasma, and i-l) human urine (n¼ 10), for positive (a, e, i) and negative (b, f, j) ion analysis of polar metabolites, and positive (c, g, k) and negative (d, h, l) ion
analysis of non-polar metabolites.
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tabolites in plasma, and approximately the same number in urine
samples) and the Bligh and Dyer method (1e41% more annotated
metabolites; similar number of metabolites were detected in non-
polar negative plasma samples) when combining results for the
polar and non-polar metabolites (Table A.2). In D. magna samples
the original and modified Matyash method yielded almost equal
numbers of metabolites, whereas the Bligh and Dyer method
yielded 3e8% less metabolites.
Specifically, the original and modified Matyash methods per-
formed equally in both polar (only in polar positive samples did the
modified Matyash perform slightly better and yielded 3% more
metabolites) and non-polar phases, both surpassing the Bligh and
Dyer protocol (recovering 3e8% more metabolites in polar and
7e8% in non-polar samples) in D. magna samples (Fig. 2 (aed)).
Similar to the peak counts, all three extraction methods proved to
be highly consistent, as 81e88% of the annotated metabolites were
present in all three datasets. In plasma samples (Fig. 2 (eeh)) the
modified Matyash method yielded 9e30% and 1e41% more me-
tabolites than the original Matyash and Bligh and Dyer methods,
respectively (except for non-polar negative samples (Fig. 2 (h)) for
which the Bligh and Dyer method detected 3% more metabolites).
In urine samples (Fig. 2 (iel)) the original Matyash method was
superior compared to the other two methods (yielding 1e6% and
7e19% more metabolites than the modified Matyash and Bligh and
Dyer methods, respectively). Overall, the modified Matyash
method was superior in D. magna polar and plasma samples, and
comparable (to the original Matyash) in D. magna non-polar sam-
ples; the original Matyash method showed higher metabolite yield
in urine samples; and the Bligh and Dyer method was comparable
to the modified Matyash method for non-polar plasma samples.
Several non-polar (putatively annotated) compounds were
selected from various lipid groups (including phosphatidic acids -
PA, phosphatidylcholines - PC, phosphatidylethanolamines - PE,
phosphatidylglycerols - PG, phosphatidylinositols - PI, phosphati-
dylserines - PS, sphingomyelins e SM and triglycerides - TG) and
compared across the three extraction strategies using PQN
normalized signal intensities (Fig. A2). In general, in D. magna
samples (only 2 metabolites had lower intensities in modified
Matyash method) as well as in plasma (only 4 metabolites showed
significantly lower intensities in Bligh and Dyer compared to the
other two methods), all three methods showed very similar lipid
intensities. In urine samples, however, the modified Matyash and
Bligh and Dyer methods showed similar intensities whereas the
original Matyash intensities were lower (for 11 out of 17 metabo-
lites significantly lower than both other methods, and for 2 me-
tabolites lower than modified Matyash).
In addition, all putatively annotated amino acids in each sample
type were selected in order to evaluate and compare polar
metabolite intensities (Fig. A3). In D. magna polar samples both the
original and modified Matyash methods performed equally well,
surpassing the Bligh and Dyer method (showing significantly
higher metabolite intensities in 14 out of 24 amino acids; the
remaining 10 were similar intensity across all three methods). In
plasma and urine, however, the majority of amino acid intensities
were similar across all threemethods (only 3metabolites had lower
intensities in the original Matyash method compared to the other
two).
To date, numerous studies have investigated the sample
extraction efficiencies of the Bligh and Dyer or Folch methods [34].
Recently, the Matyash method has gained considerable popularity
though most of the studies have focused on the extraction ofmetabolites from biofluids, in particular plasma. For instance,
Heiskanen et al. [35] used a Folch extraction and shotgun lip-
idomics approach to measure lipids in human plasma, recovering
610 and 639 lipids in negative and positive ion modes, respectively.
Jung et al. [36] also used the Folch method to perform high-
throughput molecular lipidomics in plasma and quantified several
hundreds of lipids. Few studies have compared the Matyash
method to the long-standing Bligh and Dyer and Folch methods in
plasma samples. In one study [24] all three methods (Matyash,
Bligh and Dyer, Folch) as well as two global metabolite extraction
methods for both lipids and polar metabolites using DIMS and GC-
MS were examined and evaluated. The authors concluded that the
Folch and Matyash methods performed equally well when assess-
ing lipids (in terms of the number of metabolites extracted); while
for the extraction of polar metabolites the acetonitrile /iso-
propanol/water (3/3/2, v/v/v) method was recommended. Another
study [37] also compared the Matyash and Folch methods (in
plasma), employing LC-MS, and concluded that both extracted
lipids equally well, however Matyash surpassed the Folch method
when extracting polar metabolites; therefore they recommended
the Matyash method for untargeted metabolomics and lipidomics.
Yang et al. [38] optimised theMatyashmethod and compared it to a
simple methanol precipitation protocol, using LC-MS to show that
the new Matyash method recovered 3806 versus only 1851 meta-
bolic features in plasma. Furthermore, Whiley et al. [39] also
modified the Matyash method employing it in so called in-vial dual
extraction (IVDE) of plasma, and analysed the samples via HPLC-
QTOF MS, recovering over 4500 features.
Several studies have investigated metabolite extraction strate-
gies from urine. For instance, Bang et al. [40] compared the Folch
and Matyash methods using nanoflow LC-ESIeMS3 and concluded
that the Folch was superior when extracting different phospholipid
classes in negative ion mode. Another study [41] showed that HPLC
water combined with pre-concentration by solid-phase extraction
(SPE) retained 3503e4484 peaks (in positive and negative modes,
respectively) using nanoflow UHPLC-nanoESI-TOF-MS. Most of
these studies are in agreement with our results, concluding that the
Matyash method surpasses both the Folch and Bligh and Dyer
methods in terms of peak recovery from biofluids.
Various studies have focused on metabolite extraction of animal
tissues (primarily of dissected organs) predominantly employing
either the Bligh and Dyer or Folch methods, however only a few
have investigated metabolite extraction in the whole organism.
Taylor et al. [29] showed that D. magna extracted using the Bligh
and Dyer method yields 1848 and 3599 polar features (positive and
negative ion modes, respectively) following DIMS analysis. No
earlier studies have compared the extraction yields of the Matyash
and Bligh and Dyer methods in tissue samples. Here we have re-
ported evidence, consistent with earlier studies of biofluids, that
the Matyash (or modified Matyash) method is superior (recovering
5e20% more peaks) or comparable (in plasma non-polar samples)
to the Bligh and Dyer method.3.2. Reproducibility
Reproducibility of the extraction methods was compared based
on the relative standard deviations (RSDs) of the intensities of the
peaks (Fig. 3), in particular the median of these values (mRSD; also
termed coefficient of variance) which we have shown previously to
serve as a useful statistic for benchmarking the reproducibility of
methods [28]. Overall, the median RSD values of the modified
Matyash method were lower than those for the Bligh and Dyer and
Fig. 3. Extraction method comparison based on the reproducibility of the metabolic
peak intensities. Bar charts represent mRSD of each of the three extraction methods
(stepwise Bligh and Dyer, modified and original Matyash) for the analysis of polar and
non-polar metabolites (pos. e positive and neg. e negative ion modes) in a) D. magna,
b) human plasma, and c) urine (n¼ 10).
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non-polar datasets (Fig. A1).
Specifically, the reproducibility of D. magna metabolomics data
(Fig. 3 (a)) was very similar across all methods, for polar (with
mRSD 20e24%) and non-polar (mRSD e 22e29%) metabolites. RSD
values over 20% are not unexpected as the variation across these
samples could predominantly arise from biological differences
(each sample comprises of a pool of 30 individual organisms) ratherthan differences introduced through the sample preparation. The
trends in mRSD values were less clear in plasma (Fig. 3 (b)),
although the modified Matyash datasets showed the lowest values
(19e33%, except positive ion data of polar metabolites with mRSD
of 54%), followed by Bligh and Dyer (33e37%) and then the original
Matyash method with surprisingly high metabolic variation
(36e55%). In urine samples (Fig. 3 (c)), the modified Matyash
method again performed better (with mRSD 6e11%) than both
other methods (mRSD values of 9e16% and 18e28% for Bligh and
Dyer and the original Matyash method, respectively). In summary,
all three methods showed similar reproducibility in D. magna
potentially due to the confounding factor of biological variability,
while the reproducibility of the modified Matyash method was
superior in urine and non-polar plasma samples, and the Bligh and
Dyer method showed higher reproducibility in polar plasma
samples.
Various studies of plasma have reported high sample repro-
ducibility for the Folch, Bligh and Dyer and Matyash methods,
generally with mRSD below 15% [35]. Lee et al. [24] stated that
reproducibility of Bligh and Dyer method (mRSD of 18%) was lower
than Matyash method (mRSD of 12%), whereas another study [37]
indicated that reproducibility of the Folch and Matyash methods
was equally high. Yang et al. [38] showed that in plasma samples
the Matyash method RSDs generally were below 15% while
extraction using methanol precipitation led to RSDs of 30%. The
reproducibility of these results is comparable with modified
Matyash method in non-polar plasma fractions; polar samples
however, showed surprisingly high mRSD values in all three
methods tested. On the contrary, in urine samples the modified
Matyash method showed excellent reproducibility of polar frac-
tions (as well as non-polar, withmRSDs below 11%), consistent with
the previous biofluid studies. Furthermore, in D. magna samples
[29] mRSD values of polar fractions extracted using Bligh and Dyer
were calculated and the reported value was <25% for 20e50 neo-
nates, consistent with the current study.
4. Conclusions
In this study we have compared a Bligh and Dyer extraction to
both the original and a modified Matyash method, across three
distinct sample types, and compared the metabolite yields and
reproducibility using DIMS and UHPLC-MS analyses. The aim of this
study was to determine which extraction method provided the
highest metabolite yield and reproducibility, and which would be
the most suitable for automation on a liquid handling robot. We
have shown that the modified Matyash method ewhich was based
on the original Matyash method, but with solvent volumes more
similar to the Bligh and Dyer protocol e has a higher extraction
yield as it typically recovers the largest number of peaks (apart
from urine non-polar and D. magna samples, where it is compa-
rable) in both polar (5e29%) and non-polar (1e14%) fractions, as
well as the largest number of putatively annotated metabolites
(apart from urine samples) in polar (1e41%) and non-polar (1e14%)
samples, compared with the other two methods tested. It also
provided superior or comparable metabolite intensities in both
polar (while Bligh and Dyer showed significantly lower intensities
in D. magna) and non-polar (original Matyash performed signifi-
cantly poorer in urine samples) annotated metabolites. Further-
more, we have demonstrated that the reproducibility of the
modified Matyash method is higher or comparable to the Bligh and
Dyer and original Matyash methods (excluding polar plasma sam-
ples). Collectively this provides evidence for the use of this less
toxic modified Matyash method, for the majority of sample types
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Furthermore, this study serves as a basis for the development of
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Extraction method comparison based on peak counts across the three methods tested.
methods (stepwise Bligh and Dyer, modified and original Matyash) in 3 sample types (D
Tissue Polarity Ion mode Total peak number* Extraction yield, nu
Bligh & Dyer Mo
D. magna Polar Positive 2993 2416 28
Negative 2428 1968 22
Non-polar Positive 2308 1969 21
Negative 2786 2389 25
Plasma Polar Positive 3592 1810 25
Negative 3072 1656 21
Non-polar Positive 5079 4000 42
Negative 4786 3724 37
Urine Polar Positive 4533 3680 39
Negative 4731 3491 39
Non-polar Positive 5747 3477 38
Negative 4964 3107 38
*Total number of peaks extracted by all three methods
Table A.2
Extraction method comparison based on number of putatively annotated metabolites ac
putatively annotated in three methods (stepwise Bligh and Dyer, modified and original M
Tissue Polarity Ion mode Total metabolite number Number of annot
Bligh & Dyer M
D.magna Polar Positive 155 141 1
Negative 192 173 1
Non-polar Positive 417 365 3
Negative 563 499 5
Plasma Polar Positive 984 494 7
Negative 527 215 4
Non-polar Positive 1815 1439 1
Negative 1313 1011 9
Urine Polar Positive 2032.0 1665 1
Negative 1847.0 1412 1
Non-polar Positive 1932.0 1357 1
Negative 1394.0 808 1Acknowledgements
We would like to thank Drs. Martin Jones and Ralf Weber for
their help in metabolite annotation.AppendixTable shows extraction yield (number and percentage of peaks recovered) of three
. magna, human plasma, and human urine).
mber of peaks Extraction yield, % of total peaks recovered
dified Matyash Matyash Bligh & Dyer Modified Matyash Matyash
29 2875 80.72 94.52 96.06
18 2344 81.05 91.35 96.54
67 2137 85.31 93.89 92.59
97 2604 85.75 93.22 93.47
22 1536 50.39 70.21 42.76
69 1272 53.91 70.61 41.41
05 3609 78.76 82.79 71.06
06 3374 77.81 77.43 70.50
23 3936 81.18 86.54 86.83
99 3902 73.79 84.53 82.48
54 4228 60.50 67.06 73.57
01 4000 62.59 76.57 80.58
ross the three methods tested. Table shows number and percentage of metabolites
atyash) in 3 sample types (D. magna, human plasma, and human urine).
ated metabolites % of metabolites annotated
odified Matyash Matyash Bligh & Dyer Modified Matyash Matyash
50 146 90.97 96.77 94.19
89 188 90.10 98.44 97.92
96 398 87.53 94.96 95.44
36 538 88.63 95.20 95.56
37 555 50.20 74.90 56.40
29 270 40.80 81.40 51.23
458 1263 79.28 80.33 69.59
76 861 77.00 74.33 65.58
782 1809 81.94 87.70 89.03
595 1634 76.45 86.36 88.47
516 1615 70.24 78.47 83.59
003 1079 57.96 71.95 77.40
Fig. A.1. Extraction method comparison based on the reproducibility of peak intensities. Box plots represent mRSD (shown as a horizontal line within each box) for the three
extraction methods (stepwise Bligh and Dyer, modified and original Matyash) in a-d) D. magna, e-h) human plasma, and i-l) urine, for positive (a, e, i) and negative (b, f, j) ion
analysis of polar metabolites, and positive (c, g, k) and negative (d, h, l) ion analysis of non-polar metabolites. The outliers are shown as filled blue circles and comprise <10% of each
dataset.
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Fig. A.2. Comparison of intensities of non-polar metabolites extracted from three sample types using three different methods. Blue bars represent Bligh and Dyer method, orange -
Matyash modified, and grey - original Matyash methods in a) D. magna, b) human plasma, and c) human urine (n¼ 10). Error bars show the standard error. Stars highlight significant
changes in intensity (p < 0.05). More details on the metabolites can be found in Table A.3-A.5.
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Fig. A.3. Comparison of intensities of amino acids extracted from three sample types using three different methods. Blue bars represent Bligh and Dyer method, orange - Matyash
modified, and grey - original Matyash methods in a) D. magna, b) human plasma, and c) human urine (n¼ 10). Error bars show standard error. Stars highlight significant change in
intensity (p< 0.05). More details on the metabolites can be found in Table A.6-A.8.
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Table A.3
MI-Pack annotation of the non-polar peaks detected in D. magna via DIMS and presented in Fig. A2 (a).
m/z Empirical
formula
Ion form Theoretical
mass (Da)
Mass error
(ppm)
Metabolite name
496.3399 C24H50NO7P [MþH]þ 495.3325 0.22 ['PC(0:0/16:0)', 'PC(16:0/0:0)', 'PC(16:0/0:0)[rac]', 'PC(O-14:0/2:0)', 'PE(19:0/0:0)']
519.2492 C23H45O8P [MþK]þ 480.2852 1.51 ['PA(10:0/10:0)']
599.3904 C35H58O5 [Mþ(41K)]þ 558.4284 1.18 ['DG(12:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)[iso2]']
650.4389 C33H64NO9P [MþH]þ 649.4319 0.41 [' PC(16:0/9:0(CHO))']
675.5438 C37H75N2O6P [MþH]þ 674.5363 0.29 ['PE-Cer(d14:1(4E)/21:0)', 'PE-Cer(d15:1(4E)/20:0)', 'PE-Cer(d16:1(4E)/19:0)', 'SM(d16:1/16:0)',
'SM(d18:1/14:0)']
710.4762 C39H68NO8P [MþH]þ 709.4683 0.91 ['PE(14:0/20:5(5Z,8Z,11Z,14Z,17Z))', 'PE(14:1(9Z)/20:4(5Z,8Z,11Z,14Z))', 'PE(16:1(9Z)/
18:4(6Z,9Z,12Z,15Z))', 'PE(18:4(6Z,9Z,12Z,15Z)/16:1(9Z))', 'PE(20:4(5Z,8Z,11Z,14Z)/14:1(9Z))',
'PE(20:5(5Z,8Z,11Z,14Z,17Z)/14:0)']
760.4892 C38H76NO9P [MþK]þ 721.5258 0.39 ['PS(O-16:0/16:0)', 'PS(O-18:0/14:0)', 'PS(O-20:0/12:0)']
765.4705 C40H67O8P [M þ Hac-
H]-
706.4574 0.98 ['PA(15:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))', 'PA(17:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))', 'PA(17:2(9Z,12Z)/
20:4(5Z,8Z,11Z,14Z))', 'PA(20:4(5Z,8Z,11Z,14Z)/17:2(9Z,12Z))', 'PA(20:5(5Z,8Z,11Z,14Z,17Z)/17:1(9Z))',
'PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/15:0)']
769.5565 C46H80O6 [Mþ(41K)]þ 728.5955 0.35 ['TG(12:0/13:0/18:4(6Z,9Z,12Z,15Z))[iso6]']
774.5042 C39H78NO9P [MþK]þ 735.5414 0.54 ['PS(O-16:0/17:0)', 'PS(O-18:0/15:0)', 'PS(O-20:0/13:0)']
807.5723 C49H82O6 [Mþ(41K)]þ 766.6111 0.17 ['TG(12:0/12:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))[iso3]', 'TG(12:0/14:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))[iso6]',
'TG(14:1(9Z)/14:1(9Z)/18:4(6Z,9Z,12Z,15Z))[iso3]']
817.644 C43H87N2O6P [M þ Hac-
H]-
758.6302 0.1 ['SM(d16:1/22:0)', 'SM(d18:1/20:0)']
821.5529 C43H81O12P [MþH]þ 820.5466 1.16 ['PI(O-16:0/18:2(9Z,12Z))', 'PI(P-16:0/18:1(9Z))', 'PI(P-18:0/16:1(9Z))', 'PI(P-20:0/14:1(9Z))']
845.6628 C48H93O9P [MþH]þ 844.6557 0.24 ['PG(O-20:0/22:2(13Z,16Z))', 'PG(P-20:0/22:1(11Z))']
847.6793 C48H95O9P [MþH]þ 846.6714 0.81 ['PG(O-20:0/22:1(11Z))', 'PG(P-20:0/22:0)']
879.6719 C49H99N2O6P [M þ K-2H]- 842.7241 0.91 ['SM(d18:0/26:1(17Z))', 'SM(d18:1/26:0)', 'SM(d20:0/24:1)']
948.6519 C48H96NO13P [MþNa]þ 925.6619 0.76 ['PI-Cer(t18:0/24:0(2OH))', 'PI-Cer(t20:0/22:0(2OH))']
Table A.4
PUTMEDID annotation of the non-polar peaks detected in human plasma via LC-MS and presented in Fig. A2 (b).
m/z rt Adduct Mass error
(ppm)
Metabolite name
402.3562 459.478 NH3 3.84 MG[20:1]; Tetrahydropersin; Tricosanedioic acid;;
443.2041 495.6556 H 0.12 PG[12:0];;Armillane;;"11,12-Dimethylrosmanol"; "11beta,20-Dihydroxy-3-oxopregn-4-en-21-oic acid"; 17-oxo-Resolvin
D1; 6-methylprednisolone; 8-oxo-Resolvin D1; jasmolin II; Macrophorin B;;
460.2805 509.4291 Na 1.42 PE(P-16:0e/0:0);;
511.2932 539.3329 NaCl 1.23 PA(O-20:0/0:0);;" 1alpha,25-dihydroxy-26,27-dimethyl-17,20,22,22,23,23-hexadehydro-24a-homocholecalciferol"; "
1alpha,25-dihydroxy-26,27-dimethyl-20,21,22,22,23,23-hexadehydro-24a-homocholecalciferol"; " 24bE)-1alpha,25-
dihydroxy-22,23,24,24a,24b,24c-hexadehydro-24a,24b,24c-trihomocholecalciferol"; "3-Oxo-12,18-ursadien-28-oic
acid"; Tyromycic acid; VD 2728; VD 2736;;27-Deoxy-5alpha-cyprinol; 27-Deoxy-5b-cyprinol; "5a-Cholestane-
3a,7a,12a,25-tetrol"; "5b-Cholestane-3a,7a,12a,23-Tetrol"; "5b-Cholestane-3a,7a,12a,25-tetrol"; "5beta-cholestane-
3alpha,7alpha,12alpha,26-tetrol"; "Cholestane-3,7,12,25-tetrol"; Myxinol;; 1alpha-hydroxy-3-deoxycholecalciferol; 3-
epicholecalciferol; 1-(5alpha)-cholestenone; 22-dehydrocholesterol; "24,26-cyclocholesterol"; 3-Deoxy-25-
hydroxyvitamin D3; 3-epi-vitamin D3; 3-epicholecalciferol; 3-ketocholesterol; "4,6-cholestadienol"; "5, 20(22)-
cholestadienol"; "5,6-trans-Vitamin D3"; "5a-Cholesta-7,24-dien-3b-ol"; 5alpha-Cholest-7-en-3-one; "5alpha-cholesta-
7,24-dien-3beta-ol"; 5Alpha-cholesta-8-en-3-one; 7-Dehydrocholesterol; 8-Dehydrocholesterol; calciol; Cholestenone;
Cystosterol; Dehydrocholesterol; Desmosterol; isocholecalciferol; isotachysterol3; Lumisterol 3; Occelasterol; Previtamin
D3; tacalciol; Tachysterol 3; toxisterol3 D1; toxisterol3 E1; Vitamin D3; Zymosterol intermediate 2;;
582.2923 490.9632 NaCl 1.77 PE[20:0];;Ecalcidene;;
589.3464 560.9315 Na 2.11 PG[22:1];;"11alpha-Hemiglutaryloxy-1,25-dihydroxyvitamin D3"; Ganoderic acid Mi; Ganoderic acid Mj;;Didodecyl
thiobispropanoate;;" 1alpha,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a,24b,24c-
trihomocholecalciferol"; " 1alpha,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a,24b,24c-trihomo-20-
epicholecalciferol"; " 1alpha,25-dihydroxy-22-ethoxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-
epicholecalciferol"; Acetylursolic acid; beta-Boswellic acid acetate; Tsugaric acid A; Ursololactone;;
616.3472 521.6131 NH3 2.46 PI[18:1];;
630.3016 521.4316 Na_HCOONa 4.20 PS[19:0];;
635.4608 592.7129 Na_Na 2.14 DG[34:3];;
651.4147 558.5981 NaCl 3.08 PA(O-16:0/13:0);;Ubiquinol-6;;DG[33:3];;Anhydrorhodovibrin;;hexatriacontahexaenoic acid; Linolenyl linolenate;
Retinyl palmitate;;
740.5157 594.2042 Na_HCOONa 2.63 PC(O-14:0/O-14:0);;
751.5664 602.4034 K 3.50 DG[43:5];;
817.6449 657.7228 HCOOH 1.13 SM(d16:1/23:0); SM(d17:1/22:0); SM(d18:1/21:0); SM(d19:1/20:0); SM(d20:1/19:0);;
845.6356 638.5628 HCOOH 3.96 PS(O-18:0/22:2); PS(O-20:0/20:2); PS(P-18:0/22:1); PS(P-20:0/20:1);;SM(d18:0/22:1(OH));;
854.5483 531.7281 Na_Na 1.25 PI-Cer(d18:0/18:0); PI-Cer(d20:0/16:0);;
893.754 804.3246 Na_Na 0.49 TG[53:3];;Glycerol triheptadecanoate;;
900.6752 700.9033 Na_Na 4.45 PC(24:0/P-18:1); PC(24:1/P-18:0); PC(o-18:2/24:0); PC(O-20:0/22:2); PC(P-18:0/24:1); PC(P-18:1/24:0); PC(P-20:0/
22:1);;
929.7527 745.4404 Na_Na 1.95 TG[57:6];;TG[54:3]; TG[55:3]; Tripetroselinin;;
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Table A.5
PUTMEDID annotation of the non-polar peaks detected in human urine via LC-MS and presented in Fig. A2 (c).
m/z rt Adduct Mass error
(ppm)
Metabolite name
453.3089 530.0064 NH3 2.25 PE(P-16:0e/0:0);;
465.3921 574.9083 HCOONa 1.43 MG[24:0];;N-arachidonoyl-dopamine-d8;;18-methyl-hexacosanoic acid; 18-methyl-pentacosanoic acid; "18,24-
Dimethylhexacosanoic acid"; 23-methyl-pentacosanoic acid; 4-Methyl-3-heptyl stearate; 6-Hydroxy-8-hexacosanone;
Hexacosanoic acid; Isocerotic acid; Lauryl myristate; Mycocerosic acid (C26); Mycosanoic acid (C26); Myristyl laurate;;
511.2928 539.6198 NaCl 0.43 PA(O-20:0/0:0);;" 1alpha,25-dihydroxy-26,27-dimethyl-17,20,22,22,23,23-hexadehydro-24a-homocholecalciferol"; "
1alpha,25-dihydroxy-26,27-dimethyl-20,21,22,22,23,23-hexadehydro-24a-homocholecalciferol"; " 24bE)-1alpha,25-
dihydroxy-22,23,24,24a,24b,24c-hexadehydro-24a,24b,24c-trihomocholecalciferol"; "3-Oxo-12,18-ursadien-28-oic
acid"; Tyromycic acid; VD 2728; VD 2736;;27-Deoxy-5alpha-cyprinol; 27-Deoxy-5b-cyprinol; "5a-Cholestane-
3a,7a,12a,25-tetrol"; "5b-Cholestane-3a,7a,12a,23-Tetrol"; "5b-Cholestane-3a,7a,12a,25-tetrol"; "5beta-cholestane-
3alpha,7alpha,12alpha,26-tetrol"; "Cholestane-3,7,12,25-tetrol"; Myxinol;; 1alpha-hydroxy-3-deoxycholecalciferol; 3-
epicholecalciferol; 1-(5alpha)-cholestenone; 22-dehydrocholesterol; "24,26-cyclocholesterol"; 3-Deoxy-25-
hydroxyvitamin D3; 3-epi-vitamin D3; 3-epicholecalciferol; 3-ketocholesterol; "4,6-cholestadienol"; "5, 20(22)-
cholestadienol"; "5,6-trans-Vitamin D3"; "5a-Cholesta-7,24-dien-3b-ol"; 5alpha-Cholest-7-en-3-one; "5alpha-cholesta-
7,24-dien-3beta-ol"; 5Alpha-cholesta-8-en-3-one; 7-Dehydrocholesterol; 8-Dehydrocholesterol; calciol; Cholestenone;
Cystosterol; Dehydrocholesterol; Desmosterol; isocholecalciferol; isotachysterol3; Lumisterol 3; Occelasterol; Previtamin
D3; tacalciol; Tachysterol 3; toxisterol3 D1; toxisterol3 E1; Vitamin D3; Zymosterol intermediate 2;;
561.3157 530.5856 HCOONa 1.10 PG[20:1];;Phytolaccinic acid; Pokeberrygenin;;PA[22:1];;" 1alpha-hydroxy-18-(4-hydroxy-4-ethyl-2-hexynyloxy)-
23,24,25,26,27-pentanorcholecalciferol"; " 1alpha,22,25-trihydroxy-26,27-dimethyl-23,23,24,24-tetradehydro-24a-
homocholecalciferol"; " 1alpha,22,25-trihydroxy-26,27-dimethyl-23,24-tetradehydro-24a-homo-20-epicholecalciferol"; "
1alpha,25-dihydroxy-22-methoxy-26,27-dimethyl-23,23,24,24-tetradehydrocholecalciferol"; " 1alpha,25-dihydroxy-22-
methoxy-26,27-dimethyl-23,24-tetradehydro-20-epicholecalciferol"; "(3alpha,3-Hydroxy-21-oxoeupha-8,24-dien-26-
oic acid"; 11-Keto-beta-boswellic acid; 16-Hydroxy-3-oxo-12-oleanen-28-oic acid; 2-Hydroxy-3-oxo-12-oleanen-28-oic
acid; 23-Hydroxy-3-oxocycloart-24-en-26-oic acid; 28-Hydroxymangiferonic acid; 3alpha-hydroxyglycyrrhetinic acid;
6beta-Hydroxy-3-oxo-12-oleanen-28-oic acid; beta-Glycyrrhetinic acid; Colubrinic acid; Glycyrrhetinic acid;
Glycyrrhetinic acid; gypsogenin; Koetjapic acid; Lansic acid; Liquiritic acid; Murrayenol; Nebrosteroid L; Pomonic acid;
Rubinic acid;;
587.4056 604.7231 K 2.82 DG[31:3];;
612.3629 500.6091 Na_HCOONa 2.78 PC(O-18:1/O-1:0);;
637.3958 549.3790 NaCl 2.00 PA(O-16:0/12:0);;
678.3885 532.1264 NaCl 1.90 PE[27:1];;
702.4695 541.0185 HCOONa 0.58 PS(P-16:0/15:1);;PE(O-16:0/13:0);;
750.5169 600.0387 NaCl 0.73 PC(o-14:0/16:0); PC(O-16:0/14:0); PC(O-18:0/12:0); PE(O-16:0/17:0); PE(O-18:0/15:0); PE(O-20:0/13:0);;
756.4676 529.2469 NH3 2.47 PI[27:1];;PE(18:3/P-16:0); PE(O-16:0/18:4); PE(P-16:0/18:3);;
757.6071 729.1700 Na_HCOONa 1.28 DG[43:2];;Campesteryl ester[20:3];;Campesteryl ester[18:0]; Campesteryl stearate; CE[19:0];;
845.6369 638.8819 HCOOH 2.43 PS(O-18:0/22:2); PS(O-20:0/20:2); PS(P-18:0/22:1); PS(P-20:0/20:1);;TG[48:2];;SM(d18:0/22:1(OH));;
859.6027 549.9083 NH3 0.92 PI-Cer(t18:0/18:0(2OH)); PI-Cer(t20:0/16:0(2OH));;SM(d18:0/22:1(OH));;PG(O-16:0/22:1); PG(O-18:0/20:1); PG(O-20:0/
18:1); PG(P-16:0/22:0); PG(P-18:0/20:0); PG(P-20:0/18:0);;TG[48:8];;TG[46:5];;
869.6239 633.0871 HCOONa 0.38 PG[43:4];;PG[41:1];;Glc-Campesterol[18:2];;SM(d18:2/24:1);;PA[43:1];;TG[47:4];;
907.7161 632.9944 K 1.03 TG[53:4]; TG[55:4];;
965.7323 805.5465 NaCl 1.34 TG[57:6];;
Table A.6
MI-Pack annotation of the polar peaks detected in D. magna via DIMS and presented in Fig. A3 (a).
m/z Empirical
formula
Ion form Theoretical
mass (Da)
Mass error
(ppm)
Metabolite name
84.0421 C2H7NO [MþNa]þ 61.0528 0.89 ['Ethanolamine']
90.0549 C3H7NO2 [MþH]þ 89.0477 0.73 ['D-Alanine', 'L-Alanine', 'Sarcosine', 'beta-Alanine']
98.0212 C2H5NO2 [MþNa]þ 75.0320 0.51 ['Glycine']
114.0560 C5H9NO2 [MH]- 115.0633 0.37 ['D-Proline', 'L-Proline']
116.0717 C5H11NO2 [MH]- 117.0790 0.11 ['Betaine', 'L-Valine']
120.0125 C3H7NO2S [MH]- 121.0198 0.04 ['L-Cysteine']
120.0654 C4H9NO3 [MþH]þ 119.0582 0.92 ['L-Allothreonine', 'L-Homoserine', 'L-Threonine']
124.0073 C2H7NO3S [MH]- 125.0147 0.56 ['Taurine']
128.0317 C3H7NO3 [MþNa]þ 105.0426 1.06 ['D-Serine', 'L-Serine']
131.0461 C4H8N2O3 [MH]- 132.0535 0.66 ['3-Ureidopropionate', 'L-Asparagine', 'N-Carbamoylsarcosine']
132.0302 C4H7NO4 [MH]- 133.0375 0.55 ['L-Aspartate']
132.1018 C6H13NO2 [MþH]þ 131.0946 1.1 ['6-Aminohexanoate', 'L-Isoleucine', 'L-Leucine']
147.0765 C5H10N2O3 [MþH]þ 146.0691 0.21 ['(R)-3-Ureidoisobutyrate', 'D-Glutamine', 'L-Glutamine']
147.1128 C6H14N2O2 [MþH]þ 146.1055 0.23 ['L-Lysine']
150.0583 C5H11NO2S [MþH]þ 149.0511 0.08 ['L-Methionine']
154.0475 C5H9NO3 [MþNa]þ 131.0582 0.16 ['(S)-4-Amino-5-oxopentanoate', '5-Amino-2-oxopentanoic acid', '5-Aminolevulinate',
'Hydroxyproline', 'L-Glutamate 5-semialdehyde']
156.0768 C6H9N3O2 [MþH]þ 155.0695 0.43 ['L-Histidine']
163.1077 C6H14N2O3 [MþH]þ 162.1004 0 ['L-Hydroxylysine']
166.0863 C9H11NO2 [MþH]þ 165.0790 0.21 ['L-Phenylalanine']
172.0018 C4H9NO2S [Mþ(37Cl)]- 135.0354 0.54 ['L-Homocysteine']
175.1190 C6H14N4O2 [MþH]þ 174.1117 0.1 ['D-Arginine', 'L-Arginine']
182.0812 C9H11NO3 [MþH]þ 181.0739 0.11 ['L-Tyrosine']
205.0972 C11H12N2O2 [MþH]þ 204.0899 0.03 ['L-Tryptophan']
227.1141 C9H14N4O3 [MþH]þ 226.106,591 0.98 ['Carnosine']
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Table A.7
PUTMEDID annotation of the polar peaks detected in human plasma via LC-MS and presented in Fig. A3 (b).
m/z rt Adduct Mass error
(ppm)
Metabolite name
132.1020 404.2944 NH3 0.90 Beta-Leucine; D-Leucine; L-Alloisoleucine; L-Norleucine;;2-Methyl-2-pentenoic acid; 2-Methyl-3-pentenoic acid; 2-
Methyl-4-pentenoic acid; "2,3-Hexanedione"; 3-isopropyl acrylic acid; "3,4-Hexanedione"; 4-hydroxyhexenal; 4-Methyl-
2-pentenoic acid; "4-Methyl-2,3-pentanedione"; Adipaldehyde; Allyl propionate; Delta-Hexanolactone; delta-hexenoic
acid; Ethyl crotonate; Gamma-Caprolactone; gamma-hexenoic acid; Hydrosorbic acid; Methyl 4-pentenoate; Prenyl
formate; Pyroterebic acid; trans-Hex-2-enoic acid; trimethyl acrylic acid;;
137.0927 73.7697 NH3 4.66 L-Homoserine; L-Allothreonine;;
147.0766 602.4155 [MþH]þ 0.89 L-Glutamine; Alanylglycine; D-Glutamine; Ureidoisobutyric acid;;
147.1130 714.1273 [MþH]þ 1.53 L-Lysine; 3,5-Diaminohexanoate; "3,6-Diaminohexanoate"; D-Lysine;;
148.0605 625.9020 [MþH]þ 0.23 L-Glutamic acid; L-4-Hydroxyglutamate semialdehyde; N-Acetylserine; O-Acetylserine;;
150.0140 608.9164 Na_HCOONa 1.93 L-Serine; D-Serine;;Acetaldehyde oxime; Acetamide; N-Methylformamide;;
159.0766 623.7098 [MþH]þ 0.90 Citrulline; Argininic acid; "1-(Hydroxymethyl)-5,5-dimethyl-2,4-imidazolidinedione";;
161.9931 609.8744 Na 4.40 O-Phosphoethanolamine;;
173.1037 698.3409 H 4.16 L-Arginine; D-Arginine;;
189.1348 684.9616 [MþH]þ 1.03 Homo-L-arginine; L-Targinine;;
199.9544 827.3276 KCl 0.65 Taurine;;
205.0972 379.3728 [MþH]þ 0.33 (±)-Tryptophan; 3-Hydroxymethylantipyrine; D-Tryptophan;;
207.9983 627.1723 [MþNa]þ 0.59 Phosphoserine; DL-O-Phosphoserine;
240.1019 317.3329 NH3 2.44 L-Cystathionine; Allocystathionine; Cysteinyl-Threonine; Threoninyl-Cysteine;;
241.0315 762.1263 [MþH]þ 1.22 L-Cystine;;
244.0242 792.6005 KCl 3.05 S-(3-oxo-3-carboxy-n-propyl)cysteine;;1-Methylhistidine; 3-Methylhistidine;;Nor-psi-tropine;;
313.0523 238.1227 Na_Na 2.21 L-Homocystine; Aspartyl-Histidine; Histidinyl-Aspartate;;Temurin;;"7-Isopropyl-1,4-dimethylazulene";;DL-
Homocystine;;
Table A.8
PUTMEDID annotation of the polar peaks detected in human urine via LC-MS and presented in Fig. A3 (c).
m/z rt Adduct Mass error
(ppm)
Metabolite name
104.0707 510.2082 NH3 0.99 b-aminoisobutyric acid; 2-Aminoisobutyric acid; 3-Aminobutanoic acid; 3-Aminoisobutanoic acid; Butyl nitrite; D-Alpha-
aminobutyric acid; Dimethylglycine; Gamma-Aminobutyric acid; L-Alpha-aminobutyric acid; N-Ethylglycine;;But-2-
enoic acid; Diacetyl; Ethenyl acetate; Gamma-Butyrolactone; Isocrotonic acid; Oxolan-3-one; Vinyl acetic acid;;
106.0501 632.0966 NH3 1.96 L-Serine; D-Serine;;Malonic semialdehyde; Pyruvic acid;;
122.0268 325.2378 H 1.78 L-Cysteine; D-Cysteine;;
126.0217 475.9900 H 2.41 Taurine;;
132.1015 585.9744 NH3 3.01 Beta-Leucine; D-Leucine; L-Alloisoleucine; L-Norleucine;;2-Methyl-2-pentenoic acid; 2-Methyl-3-pentenoic acid; 2-
Methyl-4-pentenoic acid; "2,3-Hexanedione"; 3-isopropyl acrylic acid; "3,4-Hexanedione"; 4-hydroxyhexenal; 4-Methyl-
2-pentenoic acid; "4-Methyl-2,3-pentanedione"; Adipaldehyde; Allyl propionate; Delta-Hexanolactone; delta-hexenoic
acid; Ethyl crotonate; Gamma-Caprolactone; gamma-hexenoic acid; Hydrosorbic acid; Methyl 4-pentenoate; Prenyl
formate; Pyroterebic acid; trans-Hex-2-enoic acid; trimethyl acrylic acid;;
133.0607 606.9302 H 0.62 L-Asparagine; Glycyl-glycine; D-Asparagine; N-Carbamoylsarcosine; Ureidopropionic acid;;1-Pentanol; 2-Methyl-1-
butanol; Isopentanol;;
134.0184 552.1245 Na_Na 3.45 L-Alanine; Beta-Alanine; D-Alanine; Ethyl carbamate; Sarcosine;;
147.0759 597.3338 H 3.52 L-Glutamine; Alanylglycine; D-Glutamine; Ureidoisobutyric acid;;
147.1123 708.9655 NH3 3.44 L-Lysine; 3,5-Diaminohexanoate; "3,6-Diaminohexanoate"; D-Lysine;;2-Pyrrolidineacetic acid; D-Pipecolic acid; L-Pipecolic
acid; L-trans-4-Methyl-2-pyrrolidinecarboxylic acid; N4-Acetylaminobutanal; Pipecolic acid;;
162.0755 614.0318 H 3.57 Aminoadipic acid; Acetylhomoserine; 2-Methylglutaconic acid; 3-Hexenedioic acid; "3-Hydroxyadipic acid 3,6-lactone";
3-Methylglutaconic acid; Dimethyl fumarate; Ethyl hydrogen fumarate; Maleic acid homopolymer; trans-2-Hexenedioic
acid;;
164.0286 568.8984 Na_HCOONa 4.73 L-Homoserine; L-Allothreonine; 3-Aminopropionaldehyde; Aminoacetone;;
173.1042 690.3098 H 1.17 L-Arginine; D-Arginine;;
176.1030 551.2034 H 0.04 Citrulline; Argininic acid;;
178.0082 450.0013 Na_Na 2.62 L-Aspartic acid; Iminodiacetic acid; D-Aspartic acid;;
180.0659 453.1635 HCOOH 4.20 L-Tyrosine; 4-Hydroxy-4-(3-pyridyl)-butanoic acid; Beta-Tyrosine; L-Threo-3-Phenylserine; o-Tyrosine;;2-
Aminoacetophenone; 2-Phenylacetamide; 2'-Aminoacetophenone; N-Acetylarylamine;;
201.0851 442.0920 HCOONa 2.55 L-Ornithine; D-Ornithine monochlorohydrate/ornithine; Ornithine;;
223.0740 744.1265 Na 4.88 L-Cystathionine; Allocystathionine; Cysteinyl-Threonine; Threoninyl-Cysteine;;3-(1-Butenyl)-1H-2-benzopyran-1-one;
Safynol;;
241.0310 753.4439 H 0.77 L-Cystine;;
273.0837 260.4907 HCOONa 3.40 (±)-Tryptophan; 3-Hydroxymethylantipyrine; D-Tryptophan;;Alanyl-Valine; Glycyl-Isoleucine; Glycyl-L-leucine;
Isoleucyl-Glycine; Leucyl-Glycine; N-Alpha-acetyllysine; N6-Acetyl-L-lysine; Valyl-Alanine;;"1,3-Octanediol"; "octane-
1,2-diol";;
313.0530 358.1893 Na_Na 0.17 L-Homocystine; Aspartyl-Histidine; Histidinyl-Aspartate;;Temurin;;DL-Homocystine;;
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